While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

The Economic Survey 2024-25 says on a global pedestal, India has successfully established itself as one of the top 20 medical ...

There is a need to focus on innovation, new drug development and biopharmaceuticals as spending on research and development ...

New Delhi: Drug major Glenmark Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Economic Survey 2025 calls for systematic deregulation, focus on R&D: Our Bureau, New Delhi Friday, January 31, 2025, 15:30 Hrs [IST] Projecting a growth of around 6.3 to 6.8 per ...

FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...

JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...

The Economic Survey 2024-25 emphasises the need for increased innovation, new drug development, and biopharmaceutical ...

JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...